AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31068158 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 321
Study 28812913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcanalicular laser-assisted dacryocystorhinostomy (TL DCR)
Number of subjects: 163
Study 28812913 — intervention group
Group type: COMPARATOR
Intervention: Conventional external dacryocystorhinostomy (Ex DCR)
Number of subjects: 163
Study 25346499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily for five days followed by 15 mg or 20 mg once daily)
Number of subjects: 196
Study 25346499 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving international normalized ratio of 1.7)
Number of subjects: 196
Study 23788287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) for thromboprophylaxis
Number of subjects: 3746
Study 23788287 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin for thromboprophylaxis
Number of subjects: 3746
Study 23788287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (mild, moderate, severe)
Number of subjects: 3746
Study 23788287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (moderate and severe)
Number of subjects: 3746
Study 22796405 — intervention group
Group type: EXPERIMENTAL
Intervention: Resus:Station
Number of subjects: 45
Study 22796405 — intervention group
Group type: COMPARATOR
Intervention: Standard trolley
Number of subjects: 45
Study 22796405 — intervention group
Group type: COMPARATOR
Intervention: Both trolleys
Number of subjects: 45
Study 19597914 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream plus Nd:YAG laser treatment
Number of subjects: 3
Study 19597914 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream plus Nd:YAG laser treatment
Number of subjects: 3
Study 17409018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin, 1000 mg daily (n=7)
Number of subjects: 41
Study 17409018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin, 1000 mg daily + Amantadine, 200 mg daily (n=8)
Number of subjects: 41
Study 17409018 — intervention group
Group type: COMPARATOR
Intervention: No therapy (controls, n=26)
Number of subjects: 41
Study 17409018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and Amantadine (combined treatment)
Number of subjects: 41
Study 15690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonic women
Number of subjects: 80
Study 15690219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonic men
Number of subjects: 80
Study 15690219 — intervention group
Group type: COMPARATOR
Intervention: Functional and organic disorders
Number of subjects: 80
Study 12031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary phase 2 cardiac rehabilitation program (n = 52)
Number of subjects: 155
Study 12031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician supervised, nurse‐case‐managed cardiovascular risk reduction program (n = 54)
Number of subjects: 155
Study 12031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based cardiovascular risk reduction program (n = 49)
Number of subjects: 155
Study 12031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary phase 2 cardiac rehabilitation program
Number of subjects: 155
Study 12031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based cardiovascular risk reduction program
Number of subjects: 155
Study 12031725 — intervention group
Group type: COMPARATOR
Intervention: Physician supervised, nurse‐case‐managed cardiovascular risk reduction program
Number of subjects: 155
Study 9891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 mg twice daily)
Number of subjects: 60
Study 9891831 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (250 mg slow release twice daily)
Number of subjects: 60
Study 7636755 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride administered at 5 different time intervals (2, 8, 12, 24, and 48 hr)
Number of subjects: 0
Study 2922625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated prompting system
Number of subjects: 0
Study 2922625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompting)
Number of subjects: 0
Study 81361 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day oral DL-carnitine chloride
Number of subjects: 0
Study 81361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of carnitine
Number of subjects: 0
Study 81361 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31293141 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR-1 trial
Number of subjects: 1889
Study 31293141 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE registry
Number of subjects: 1889
Study 31004128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified wheat (FW)
Number of subjects: 71
Study 31004128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroponically fortified wheat (HBW)
Number of subjects: 71
Study 31004128 — intervention group
Group type: EXPERIMENTAL
Intervention: Foliar biofortified wheat (FBW)
Number of subjects: 71
Study 31004128 — intervention group
Group type: COMPARATOR
Intervention: Control wheat (CW)
Number of subjects: 71
Study 28079427 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation training
Number of subjects: 120
Study 28079427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26297107 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 60
Study 26297107 — intervention group
Group type: COMPARATOR
Intervention: TEP
Number of subjects: 60
Study 21906796 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CTAS workshop with mandatory tutorial, online discussion, and workplace project
Number of subjects: 132
Study 21906796 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard content and learning activities without additional requirements)
Number of subjects: 132
Study 22123869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen administered 30 minutes before immunization and every 4 hours thereafter for a total of 5 doses
Number of subjects: 70
Study 22123869 — intervention group
Group type: COMPARATOR
Intervention: Standard care instructions (Control group)
Number of subjects: 70
Study 22123869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen use
Number of subjects: 70
Study 19419575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group GPs who attended an introductory one-day workshop and implemented structured functional assessments during an eight months intervention period.
Number of subjects: 57
Study 16368617 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention during golf putting task
Number of subjects: 300
Study 16368617 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention during golf putting task
Number of subjects: 300
Study 15349012 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 to 112.5 mg/d)
Number of subjects: 124
Study 15349012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 10396705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 or 5 mg daily)
Number of subjects: 16
Study 10396705 — intervention group
Group type: COMPARATOR
Intervention: Control (optimal basic regimen without pimobendan)
Number of subjects: 16
Study 7587031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g IV cefotaxime every 12 h
Number of subjects: 365
Study 7587031 — intervention group
Group type: COMPARATOR
Intervention: 2 g IV ceftriaxone once daily
Number of subjects: 365
Study 2103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg.kg‐1
Number of subjects: 40
Study 2103060 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 40
Study 7010515 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day
Number of subjects: 39
Study 7010515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30594532 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 5077
Study 30594532 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of regular participation (benefit condition)
Number of subjects: 5077
Study 30594532 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms condition
Number of subjects: 5077
Study 30594532 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt to write down the date to pick up the screening test
Number of subjects: 5077
Study 27909950 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400 mg BID
Number of subjects: 151
Study 27909950 — intervention group
Group type: COMPARATOR
Intervention: corticosteroid ointment
Number of subjects: 151
Study 24216219 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk only
Number of subjects: 0
Study 24216219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle risk only
Number of subjects: 0
Study 24216219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genetic and lifestyle risk (combined)
Number of subjects: 0
Study 24216219 — intervention group
Group type: COMPARATOR
Intervention: No risk feedback (control)
Number of subjects: 0
Study 23662517 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal cross section space (ACSB) blockade with non-opioid analgesics
Number of subjects: 62
Study 23662517 — intervention group
Group type: COMPARATOR
Intervention: Conventional system anaesthesia
Number of subjects: 62
Study 21121748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 98
Study 21121748 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 98
Study 17985512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions for preventing weight regain in individuals who have successfully lost weight in a group‐based behavioral weight loss program
Number of subjects: 31
Study 17985512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural characteristics specific to African Americans
Number of subjects: 31
Study 15848482 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (lap Nx)
Number of subjects: 100
Study 15848482 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy (open Nx)
Number of subjects: 100
Study 12070058 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg twice daily via a dry powder inhaler
Number of subjects: 31
Study 12070058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 31
Study 10468683 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate (RBC) 400 mg with clarithromycin 500 mg
Number of subjects: 530
Study 10468683 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg with clarithromycin 500 mg
Number of subjects: 530
Study 8682346 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-endorphin levels in girls with weight loss related amenorrhea
Number of subjects: 20
Study 8682346 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 young, regularly menstruating healthy girls)
Number of subjects: 20
Study 8682346 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of FSH, LH, estradiol in girls with weight loss related amenorrhea
Number of subjects: 20
Study 8682346 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of PRL and cortisol in girls with weight loss related amenorrhea
Number of subjects: 20
Study 2270564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sanguinarine gel
Number of subjects: 0
Study 2270564 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 2270564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% and 0.5% sanguinarine gel
Number of subjects: 0
Study 7214806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous glucagon
Number of subjects: 0
Study 7214806 — intervention group
Group type: COMPARATOR
Intervention: 2 mg intravenous glucagon
Number of subjects: 0
Study 30557540 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-chest CPR
Number of subjects: 56
Study 27837101 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (6-month, twice weekly programme: 30 min aerobic and 30 min resistance)
Number of subjects: 105
Study 27837101 — intervention group
Group type: COMPARATOR
Intervention: Handwriting (6-month, twice weekly programme at home)
Number of subjects: 105
Study 26536605 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) of at least 30 min/day for at least five days a week
Number of subjects: 296
Study 26536605 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week of MVPA or 75 min/week of vigorous PA in bouts of at least 10 min
Number of subjects: 296
Study 26536605 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min/day of MVPA at least five days a week in bouts of at least 10 min
Number of subjects: 296
Study 26536605 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps/day
Number of subjects: 296
Study 23210726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (300 mg single dose)
Number of subjects: 10
Study 23210726 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily for 3 days)
Number of subjects: 10
Study 21537018 — intervention group
Group type: COMPARATOR
Intervention: Daily dose of oritavancin (200 mg for 3 to 7 days)
Number of subjects: 302
Study 21537018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oritavancin (1,200 mg)
Number of subjects: 302
Study 21537018 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5)
Number of subjects: 302
Study 21537018 — intervention group
Group type: COMPARATOR
Intervention: Daily dose of oritavancin (200 mg) in MRSA patients
Number of subjects: 302
Study 21537018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oritavancin (1,200 mg) in MRSA patients
Number of subjects: 302
Study 21537018 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent dose of oritavancin (800 mg with an option for an additional 400 mg on day 5) in MRSA patients
Number of subjects: 302
Study 19299779 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (infusion rate 0.014 +/- 0.011 microg x kg(‐1) x min(‐1))
Number of subjects: 60
Study 19299779 — intervention group
Group type: COMPARATOR
Intervention: Control group (remifentanil discontinued)
Number of subjects: 60
Study 17605569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led social support intervention involving support groups and telephone contacts
Number of subjects: 136
Study 17605569 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 136
Study 16382084 — intervention group
Group type: EXPERIMENTAL
Intervention: Recategorization into a superordinate category
Number of subjects: 0
Study 16382084 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining the salience of subgroups within a recategorized superordinate group
Number of subjects: 0
Study 15293769 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antidepressant agents
Number of subjects: 0
Study 15293769 — intervention group
Group type: COMPARATOR
Intervention: Older antidepressant agents
Number of subjects: 0
Study 12579927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% levofloxacin eyedrops
Number of subjects: 132
Study 12579927 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ofloxacin eyedrops
Number of subjects: 132
Study 9252005 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alfentanil (100 microg kg(‐1) induction, 1‐2 microg kg(‐1) min(‐1) infusion)
Number of subjects: 45
Study 9252005 — intervention group
Group type: COMPARATOR
Intervention: Low dose alfentanil (30 microg kg(‐1) induction, 10‐20 microg kg(‐1) bolus every hour)
Number of subjects: 45
Study 9252005 — intervention group
Group type: COMPARATOR
Intervention: No opioid (midazolam and thiopentone induction)
Number of subjects: 45
Study 1647635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuredal combined with psychotherapy
Number of subjects: 0
Study 1647635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6412606 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (1,000 micrograms)
Number of subjects: 10
Study 6412606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg)
Number of subjects: 10
Study 6412606 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline plus cromolyn
Number of subjects: 10
Study 6412606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30222235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 66
Study 30222235 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 66
Study 27335267 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 22
Study 27335267 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral with 10% collagen (DBBM-C)
Number of subjects: 22
Study 25624390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (SLI) followed by nasal continuous positive airway pressure (nCPAP)
Number of subjects: 291
Study 25624390 — intervention group
Group type: COMPARATOR
Intervention: nCPAP alone
Number of subjects: 291
Study 24227683 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBG (Iliac Crest Bone Graft)
Number of subjects: 0
Study 24227683 — intervention group
Group type: COMPARATOR
Intervention: C (Calcaneus)
Number of subjects: 0
Study 24227683 — intervention group
Group type: COMPARATOR
Intervention: DT (Distal Tibia)
Number of subjects: 0
Study 24227683 — intervention group
Group type: COMPARATOR
Intervention: PT (Proximal Tibia)
Number of subjects: 0
Study 21281028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent epidural analgesia
Number of subjects: 205
Study 21281028 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia
Number of subjects: 205
Study 19333167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin ER once daily (1800 mg PM)
Number of subjects: 158
Study 19333167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin ER twice daily (600 mg AM, 1200 mg PM)
Number of subjects: 158
Study 19333167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 17709449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, and 20 mg zinc)
Number of subjects: 13017
Study 17709449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 13017
Study 17709449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13017
Study 15327043 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care intervention
Number of subjects: 133
Study 15327043 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' psychological morbidity assessed by Profile of Mood State (POMS)
Number of subjects: 133
Study 15327043 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in caregivers
Number of subjects: 133
Study 15327043 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in the degree of depression of caregivers
Number of subjects: 133
Study 11762571 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting methylphenidate
Number of subjects: 2897
Study 11762571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2897
Study 9683944 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-quality A-scan measurement
Number of subjects: 103
Study 9683944 — intervention group
Group type: COMPARATOR
Intervention: Average of three acceptable measurements
Number of subjects: 103
Study 7601181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg bds)
Number of subjects: 0
Study 7601181 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg tds)
Number of subjects: 0
Study 7601181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide and Diclofenac
Number of subjects: 0
Study 31725655 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 60
Study 31725655 — intervention group
Group type: COMPARATOR
Intervention: Desflurane/remifentanil
Number of subjects: 60
Study 28384800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU initial dose, followed by 100,000 IU monthly)
Number of subjects: 5110
Study 28384800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 28384800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 5110
Study 25838180 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged retrograde flexible ureteroscopy (FURS)
Number of subjects: 60
Study 25838180 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 60
Study 23267736 — intervention group
Group type: EXPERIMENTAL
Intervention: Betulin emulsion skin care after CO₂-laser wounds
Number of subjects: 0
Study 23267736 — intervention group
Group type: COMPARATOR
Intervention: Moist wound dressing
Number of subjects: 0
Study 23267736 — intervention group
Group type: COMPARATOR
Intervention: Gauze covering
Number of subjects: 0
Study 21414843 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 100 mg twice daily
Number of subjects: 681
Study 21414843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study 21465692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-enhanced session on pediatric airway management and teamwork
Number of subjects: 16
Study 21465692 — intervention group
Group type: COMPARATOR
Intervention: No supplemental education (Control group)
Number of subjects: 16
Study 17405586 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced exercise program (walking) during the second and third months
Number of subjects: 32
Study 17405586 — intervention group
Group type: COMPARATOR
Intervention: Control period (no walking) during the first month
Number of subjects: 32
Study 15270962 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight hydroxyethyl starch (Hextend)
Number of subjects: 20